ClinicalTrials.gg
Status unknownNCT04942769Updated Jul 16, 2021

Study on the Effect of Selenium Supplementation on the Structure and Function of Autoimmune Thyroiditis

An interventional study of Selenium in Selenium, sponsored by Beijing Chao Yang Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-16.

Sponsored by Beijing Chao Yang Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Dec 2019, registered Jun 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To evaluate the effects of exogenous selenium supplementation on autoimmune thyroiditis.

Read the detailed description

In patients with autoimmune thyroiditis, investigators compared changes in thyroid function, anti-thyroid peroxidase antibody, anti-thyroglobulin antibody, thyroid magnetic resonance T1-mapping values and metabolic indicatorsfrom baseline to the end of treatment (12 weeks)

02

Conditions studied

  • Selenium
03

In context

Lead sponsor

Beijing Chao Yang Hospital is the lead sponsor of 140 studies on the registry; 49 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women between the ages of 18 and 75
  • Clinical diagnosis of thyroiditis, serum TPOAb and TGAB positive
  • Thyroid function is normal, and no drugs affecting thyroid function such as Umetole and Serge have been used

Exclusion criteria

Exclusion Criteria:

  • The indicated in the Chinese instructions of the drug
  • Hypothyroidism, hyperthyroidism
  • Liver function impairment
  • Renal function impairment
  • Claustrophobia
  • Mental disorders
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    selenium

    selenium was administered to patients with autoimmune thyroiditis

    Drug: Selenium

Interventions

  • selenium 100ug ,take it orally twice daily

06

What researchers measure

Primary outcomes

  1. anti-thyroglobulin antibody changes

    Changes from baseline and 3 months during follow-up

    Time frame: Changes from baseline and 3 months during follow-up

  2. T1-mapping values of Thyroid MRI

    Changes from baseline and 3 months during follow-up

    Time frame: Changes from baseline and 3 months during follow-up

07

Study locations

1 of 1 sites recruiting
  • Beijing Chao-Yang Hospital, Capital Medical University
    Beijing, Beijing, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2019 (actual). Primary completion is estimated for Jul 2021, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2021
First posted
Jun 28, 2021
StartActual
Dec 20, 2019
Primary completionEst.
Jul 30, 2021
CompletionEst.
Oct 30, 2021
Last update
Jul 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04942769
Responsible party
Guang Wang (Professor and Director, Department of Endocrinology, Beijing Chao Yang Hospital) — Principal investigator
First posted
Jun 28, 2021
Start date
Dec 20, 2019
Primary completion
Jul 30, 2021 (estimated)
Completion
Oct 30, 2021 (estimated)
Last update
Jul 16, 2021

Study contacts

Jia Liu, MD
Contact
liujia0116@126.com
861085231710
Xiaomeng Sun
Contact
beijingxiaosun2010@163.com
861085231711
Guang Wang
principal investigator · Beijing Chao Yang Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selenium

Start the discussion